Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCLA Health

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1099
Shown on this page
12
Current sort
Recently updated
Campus scope
UCLA Health, Los Angeles, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCLA Health, Los Angeles, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 817–828 of 1,099 matching trials with a site at UCLA Health, Los Angeles, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424
Site status not listed — check the official record
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions
SAR447537
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Recruiting No phase listed Observational

Registry for Stage 2 Type 1 Diabetes

NCT06481904
Status at this site: Recruiting
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
TZIELD (teplizumab-mzwv)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
37
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Recruiting Not applicable Interventional

Transvaginal Electrical Stimulation for Myofascial Pelvic Pain

NCT05354869
Status at this site: Recruiting
View directory record Official record
Conditions
Myofascial Pelvic Pain
Interventions
Urostym, Standard care
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Recruiting Phase 3 Interventional

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Ficlatuzumab, Cetuximab, Placebo
Biological · Other
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Active, not recruiting Phase 2 Interventional

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06402331
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
FPI-2265
Drug
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Recruiting No phase listed Observational

Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures

NCT04604418
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Congenital Heart Disease in Children
Interventions
No intervention. It is observational
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Active, not recruiting Phase 2 Interventional

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02845323
Site status not listed — check the official record
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Nivolumab in combination with Urelumab, Nivolumab monotherapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Recruiting Not applicable Interventional

Reward Processing and Exposure Therapy for Social Anxiety Disorder

NCT06776991
Status at this site: Recruiting
View directory record Official record
Conditions
Social Anxiety Disorder (Social Phobia), Public Speaking Anxiety, Anhedonia, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Phobic Disorders
Interventions
Positive Affect Treatment - Behavioral (PAT-B), Relaxation Treatment, Exposure Therapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Recruiting Phase 2Phase 3 Interventional

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
RP2, Ipilimumab, Nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Active, not recruiting Phase 2 Interventional Results available

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

NCT01898494
Site status not listed — check the official record
View directory record Official record
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions
Transoral surgery, intensity-modulated radiation therapy, cisplatin, carboplatin
Procedure · Radiation · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
58
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer

NCT02504697
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Biosamples from airway and blood
Other
Lead sponsor
Boston University
Other
Eligibility
50 Years to 79 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 6, 2026, 1:07 AM EST
Active, not recruiting No phase listed Observational

DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

NCT04165564
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Disease
Interventions
Institutional standard of care, Biosamples of airway and blood
Other
Lead sponsor
Boston University
Other
Eligibility
46 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 6, 2026, 1:07 AM EST

About this UCLA Health institution page

What this page lists
ClinicalTrials.gov records that list UCLA Health in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.